SQUAWK/NEWS
Account
Account
Menu
Live NewsCategoriesequity

Faeth Therapeutics, Inc. (FTH) News

Track canonical SquawkNews coverage tagged to FTH, Faeth Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 8 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol FTH Asset equity Sector Markets 90 days 8 Last 30.07 Updated Jul 28, 2026, 11:11 AM UTC Open live news feed
L Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: O Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: OUTPERFORM @ Wedbush CRWD: BUY @ Loop FTH: OUTPERFORM @ Opp HRB: EQUAL WEIGHT @ S EQUITY | Jul 28, 2026, 11:11 AM UTC L FTH int Outperform @ Oppenheimer pt $60 FTH int Outperform @ Oppenheimer pt $60 EQUITY | Jul 28, 2026, 09:45 AM UTC L Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted six new employees options to purc EQUITY | Jul 03, 2026, 08:00 PM UTC M HOOD: BTIG Initiates BTIG analyst initiates coverage on Robinhood Markets with a Buy rating EQUITY | Jun 26, 2026, 12:58 PM UTC M BDC: BUY @ Citi Citi initiates BDC with a BUY rating, among other top initiations EQUITY | Jun 26, 2026, 11:17 AM UTC M FTH: Baird Initiates Baird initiates coverage on Faeth Therapeutics with Outperform rating and $57 price target EQUITY | Jun 26, 2026, 11:06 AM UTC M CRDO: Credo Initiated Credo Technology Group Holding Ltd initiated with Outperform rating and $325 price target by Evercore ISI Group analyst Mark Lipacis EQUITY | Jun 22, 2026, 12:39 PM UTC M FTH: HC Wainwright Initiates Buy HC Wainwright & Co. initiates coverage on Faeth Therapeutics with a buy rating and a price target of $60 EQUITY | Jun 22, 2026, 11:05 AM UTC